Table 3.
Lung Function Outcomes by Subgroup
| Honeycombing on HRCT and/or Confirmation of UIP Pattern by Surgical Lung Biopsy |
No Honeycombing or Surgical Lung Biopsy |
|||
|---|---|---|---|---|
| Nintedanib (n = 425) | Placebo (n = 298) | Nintedanib (n = 213) | Placebo (n = 125) | |
| Absolute change from baseline in FVC % predicted, adjusted mean (SE) | −2.66 (0.37) | −6.14 (0.42) | −3.43 (0.51) | −6.06 (0.62) |
| Nintedanib vs. placebo difference, adjusted mean (95% CI) | 3.48 (2.49–4.46) |
2.63 (1.18–4.08) |
||
| Treatment-by-subgroup interaction |
P = 0.8369 |
|||
| Time to absolute decline in FVC ≥5% predicted or death | |
|||
| Hazard ratio (95% CI) | 0.59 (0.49–0.72) |
0.65 (0.49–0.85) |
||
| Treatment-by-subgroup interaction |
P = 0.6745 |
|||
| Time to absolute decline in FVC ≥10% predicted or death | |
|||
| Hazard ratio (95% CI) | 0.59 (0.46–0.76) |
0.63 (0.43–0.94) |
||
| Treatment-by-subgroup interaction | P = 0.7735 | |||
Definition of abbreviations: CI = confidence interval; HRCT = high-resolution computed tomography; UIP = usual interstitial pneumonia.